FDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy

Background and Aims Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the CYP27A1 gene, leading to deficient sterol 27‐hydroxylase activity. This enzyme is critical for bile acid synthesis, and its dysfunction results in reduced chenodeoxycholic acid (CDCA) levels and subsequent accumulation of cholestanol in tissues. This study highlights the recent FDA approval of Ctexli (chenodiol), a synthetic CDCA formulation, as the first treatment option for CTX. Methods A comprehensive literature search was performed using PubMed and Google Scholar, and relevant articles were identified that focused on the mechanism of action, clinical efficacy, and safety of chenodiol. Results Data from the RESTORE Phase 3 trial demonstrated that chenodiol significantly reduced plasma cholestanol and urinary bile alcohol levels, with the most pronounced results observed in patients treated before the onset of irreversible neurological damage. The FDA approval of Ctexli validated these findings and established chenodiol as a reliable therapeutic option for CTX. Conclusion The FDA approval of chenodiol marks a significant milestone in the management of CTX, providing a standardized and evidence‐based therapy for a previously neglected condition. Early diagnosis, broader screening, and global access to the drug will be key to improving outcomes and ensuring lasting clinical benefit.